MA56390A - Dérivés d'imidazo[1,2-a]pyridinyle et leur utilisation dans le traitement d'une maladie - Google Patents

Dérivés d'imidazo[1,2-a]pyridinyle et leur utilisation dans le traitement d'une maladie

Info

Publication number
MA56390A
MA56390A MA056390A MA56390A MA56390A MA 56390 A MA56390 A MA 56390A MA 056390 A MA056390 A MA 056390A MA 56390 A MA56390 A MA 56390A MA 56390 A MA56390 A MA 56390A
Authority
MA
Morocco
Prior art keywords
imidazo
disease
treatment
pyridinyl derivatives
pyridinyl
Prior art date
Application number
MA056390A
Other languages
English (en)
Inventor
Philippe Bolduc
Ryan Evans
Fang Gao
Tricia May-Dracka
Emily Anne Peterson
Magnus Pfaffenbach
Zhili Xin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA56390A publication Critical patent/MA56390A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
MA056390A 2019-06-27 2020-06-24 Dérivés d'imidazo[1,2-a]pyridinyle et leur utilisation dans le traitement d'une maladie MA56390A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962867589P 2019-06-27 2019-06-27

Publications (1)

Publication Number Publication Date
MA56390A true MA56390A (fr) 2022-05-04

Family

ID=71528117

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056390A MA56390A (fr) 2019-06-27 2020-06-24 Dérivés d'imidazo[1,2-a]pyridinyle et leur utilisation dans le traitement d'une maladie

Country Status (21)

Country Link
US (1) US20230087118A1 (fr)
EP (1) EP3990454A1 (fr)
JP (1) JP7576581B2 (fr)
KR (1) KR20220027196A (fr)
CN (1) CN114245796B (fr)
AR (1) AR119234A1 (fr)
AU (1) AU2020301230A1 (fr)
BR (1) BR112021026350A2 (fr)
CA (1) CA3145040A1 (fr)
CL (1) CL2021003452A1 (fr)
CO (1) CO2022000659A2 (fr)
CR (1) CR20220037A (fr)
IL (1) IL289164A (fr)
JO (1) JOP20210322A1 (fr)
MA (1) MA56390A (fr)
MX (1) MX2021015498A (fr)
PE (1) PE20220578A1 (fr)
PH (1) PH12021553223A1 (fr)
TW (1) TW202115075A (fr)
UY (1) UY38766A (fr)
WO (1) WO2020263980A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
AR124451A1 (es) * 2020-12-22 2023-03-29 Biogen Ma Inc DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES
KR20230134499A (ko) * 2020-12-22 2023-09-21 바이오젠 엠에이 인코포레이티드 Irak4 억제제로서의 2h-인다졸 유도체 및 질환의 치료에서의그의 용도
WO2022268088A1 (fr) * 2021-06-21 2022-12-29 武汉人福创新药物研发中心有限公司 Composé tricyclique utilisé en tant qu'antagoniste de gpr84
EP4367113A1 (fr) * 2021-07-07 2024-05-15 Biogen MA Inc. Composés pour le ciblage de la dégradation de protéines irak4
JP7555519B2 (ja) 2022-02-14 2024-09-24 アストラゼネカ・アクチエボラーグ Ｉｒａｋ４阻害剤
EP4387730B1 (fr) * 2022-09-08 2025-05-28 Redx Pharma Limited Formes solides d'un inhibiteur de rock
WO2024133560A1 (fr) * 2022-12-21 2024-06-27 Dark Blue Therapeutics Ltd Dérivés imidazo[1,2-a]pyridines et imidazo[1,2-a]pyrazines en tant qu'inhibiteurs de mllt1 et mllt3
EP4389747A1 (fr) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Composés imidazo[1,2-a]pyridiniques et imidazo[1,2-a]pyraziniques en tant qu'inhibiteurs de mllt1 et mllt3
KR20260004434A (ko) * 2023-04-24 2026-01-08 상하이 에스아이엠알 바이오테크놀로지 컴퍼니 리미티드 이미다조피리딘 또는 이미다조피라진 화합물, 이의 제조 방법, 약학 조성물 및 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476681A1 (fr) * 2002-02-19 2003-08-28 Bruce N. Rogers Carboxamides hetero-aromatiques n-pontes bicycliques condenses destines au traitement de maladies
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CN110003219A (zh) * 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
US10081624B2 (en) * 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
JP2020524692A (ja) * 2017-06-21 2020-08-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｒａｋ４調節因子としてのベンゾフラン

Also Published As

Publication number Publication date
UY38766A (es) 2021-01-29
JP2022539373A (ja) 2022-09-08
AU2020301230A1 (en) 2022-01-06
AR119234A1 (es) 2021-12-01
PH12021553223A1 (en) 2022-10-17
BR112021026350A2 (pt) 2022-05-10
TW202115075A (zh) 2021-04-16
CO2022000659A2 (es) 2022-04-29
CL2021003452A1 (es) 2022-08-19
PE20220578A1 (es) 2022-04-20
US20230087118A1 (en) 2023-03-23
CN114245796B (zh) 2024-07-30
IL289164A (en) 2022-02-01
WO2020263980A8 (fr) 2021-03-04
CR20220037A (es) 2022-06-03
JOP20210322A1 (ar) 2023-01-30
KR20220027196A (ko) 2022-03-07
WO2020263980A1 (fr) 2020-12-30
MX2021015498A (es) 2022-04-20
CN114245796A (zh) 2022-03-25
CA3145040A1 (fr) 2020-12-30
EP3990454A1 (fr) 2022-05-04
JP7576581B2 (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
MA56390A (fr) Dérivés d'imidazo[1,2-a]pyridinyle et leur utilisation dans le traitement d'une maladie
Hombach-Klonisch et al. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
EP3600304A4 (fr) Alcaloïdes berbérine dans la prévention et/ou le traitement d'une maladie intestinale
EP3820537A4 (fr) Vecteurs de thérapie génique pour le traitement de la maladie de danon
MA45550A (fr) Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b
EP3915985A4 (fr) Dérivé de pyrrolopyridine et son utilisation dans la prévention et le traitement d'une maladie liée à la protéine kinase
EP4034132A4 (fr) Agents de dégradation de l'erk5 utilisés comme agents thérapeutiques dans le cancer et les maladies inflammatoires
EP3924371A4 (fr) Vecteurs de thérapie génique pour le traitement de la maladie de danon
EP2043630A4 (fr) Dérivés de purine 6,9-disubstitués et leur utilisation pour le traitement de la peau
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
IL288872B1 (en) IMIDAZO[1,5-c]PYRIMIDIN-5-AMINE PERI-CONDENSED DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USES IN CANCER TREATMENT
RU2017115772A (ru) Комбинация для генотерапии
JP2006501240A5 (fr)
EA201591715A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ 7-БЕНЗИЛ-10-(2-МЕТИЛБЕНЗИЛ)-2,6,7,8,9,10-ГЕКСАГИДРОИМИДАЗО[1,2-a]ПИРИДО[4,3-d]ПИРИМИДИН-5(3Н)-ОНА
NO20053920D0 (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
CL2013001712A1 (es) Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida, inhbidores de la tirosina quinasa receptora de tipo iii; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, cardiovasculares, fibrosis, trastornos autoinmunes, dolor, quemaduras.
TN2018000335A1 (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
EP4076444A4 (fr) Dérivés d'indazole et leurs méthodes d'utilisation dans le traitement de l'herpès virus
MA55604A (fr) Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra
EP4069700A4 (fr) Macrocycles destinés à être utilisés dans le traitement d'une maladie
MA49884A (fr) Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer
EP3813817A4 (fr) Utilisation d'actarit dans la prophylaxie ou le traitement d'une fibrose rénale ou d'une maladie rénale
EP3479826A4 (fr) Application de méthyl 4-[9- (6-aminopuryl)]-2 (s)-hydroxybutyrate dans la préparation d'un médicament pour le traitement du psoriasis et du vitiligo.
EP4027815A4 (fr) Compositions comprenant de la cytisine dans le traitement et/ou la prévention de l'addiction chez des sujets en ayant besoin
FR2925902B1 (fr) DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE